Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation

Alzheimer's Disease (AD) contributes to most cases of dementia. Its prominent neuropathological features are the extracellular neuritic plaques and intercellular neurofibrillary tangles composed of aggregated & beta;-amyloid (A & beta;) and hyperphosphorylated tau protein, respectively. In the past few decades, disease-modifying therapy targeting A & beta; has been the focus of AD drug development. Even though it is encouraging that two of these drugs have recently received accelerated US Food and Drug Administration approval for AD treatment, their efficacy or long-term safety is controversial. Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction. Moreover, inflammation, especially neuroinflammation, accompanies AD pathological processes and is also linked to cognitive deficits. Accumulating evidence indicates that inflammation has a complex and tight interplay with tau pathology. Here, we review recent evidence on the interaction between tau pathology, focusing on tau post-translational modification and dissemination, and neuroinflammatory responses, including glial cell activation and inflammatory signaling pathways. Then, we summarize the latest clinical trials targeting tau and neuroinflammation. Sustained and increased inflammatory responses in glial cells and neurons are pivotal cellular drivers and regulators of the exacerbation of tau pathology, which further contributes to its worsening by aggravating inflammatory responses. Unraveling the precise mechanisms underlying the relationship between tau pathology and neuroinflammation will provide new insights into the discovery and clinical translation of therapeutic targets for AD and other tau-related diseases (tauopathies). Targeting multiple pathologies and precision therapy strategies will be the crucial direction for developing drugs for AD and other tauopathies.

Automated summary

Alzheimer's Disease (AD) is mostly responsible for dementia, characterized by neuritic plaques and neurofibrillary tangles containing aggregated β-amyloid (Aβ) and hyperphosphorylated tau protein. Recent focus has been on disease-modifying therapy targeting Aβ, although the efficacy and long-term safety of such drugs are still controversial. Tau has gained attention as a therapeutic target due to its association with cognitive dysfunction. Inflammation, especially neuroinflammation, is linked to AD and tau pathology. Understanding the relationship between tau pathology and neuroinflammation will contribute to discovering therapeutic targets for AD and other tau-related diseases.